UVEAL MELANOMA

This early-phase trial tests a personalized treatment using immune cells (TILs) taken from a patient's own tumor. After surgical removal, these cells are multiplied in a lab and infused back to attack the cancer. The study includes 30 adults with advanced uveal melanoma or certai…

This study tests two drugs, olaparib and pembrolizumab, together in people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. About 37 adults will take part, and the main focus is on how ma…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This early-phase study tests a new drug, NN3201, designed to attack cancer cells that have a specific protein called c-Kit. The trial includes adults with advanced or spreading cancers like gastrointestinal stromal tumors, small-cell lung cancer, and others that have not responde…

This study tests a new drug called belzupacap sarotalocan (AU-011) for people with a rare eye cancer (choroidal melanoma) or suspicious spots that could turn into cancer. The drug is activated by a laser to target and destroy cancer cells while sparing healthy tissue. About 100 p…

This study tests a drug called tebentafusp in people with a specific type of untreated eye cancer (uveal melanoma) that has spread to other parts of the body. The drug is designed to help the immune system attack cancer cells. Researchers will also use a blood test to measure tum…

This study tests whether the drug tebentafusp can prevent uveal melanoma, a rare eye cancer, from returning in high-risk patients who have already had surgery or radiation. About 290 participants will either receive the drug or be observed. The goal is to see if tebentafusp reduc…

This phase 3 trial tests the drug darovasertib given before standard surgery for people with a type of eye cancer called uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and help patients keep their eye instead of needing it removed. About…

This study looks at how common BAP1 gene mutations are in people with certain cancers (like eye melanoma, skin melanoma, kidney cancer, and others) and their family members. Researchers will collect medical history and questionnaires from 500 participants to understand cancer ris…

This study follows 15 people with choroidal melanoma who are already in a larger Phase 3 trial. Researchers will ask them about their quality of life using questionnaires over 24 months. The goal is to understand how the disease and its treatment affect daily living. No new drugs…

This study aims to find new genes that may cause a hereditary risk for uveal melanoma, a rare eye cancer. Researchers will analyze the DNA of 50 patients with this cancer to identify unknown genetic changes. The goal is to improve screening and surveillance for families affected …

This study follows 700 people with uveal melanoma (a rare eye cancer) who have a high chance of the cancer returning. Researchers will use blood tests to look for early signs of liver spread and adjust follow-up care based on each person's risk. The goal is to improve early detec…

This study looks at how the liver's immune system reacts to a chemotherapy drug called melphalan, given directly to the liver through a special procedure. It involves 10 adults with uveal melanoma that has spread to the liver. The goal is to understand immune changes, not to test…